AUTHORS
Jodi Forward, MD, Kadriye Nehir Cosgun, PhD2, Yanzhi Feng, BS3, Takeshi Ito, MD-PhD4, Yusuf Kayaer, MD5, Stephen Martindale, BA6, Anna Mathew Lawrence7, Frida Ziu8, Mark E Robinson, PhD9, Deepa Bhojwani, MD10, Tulasigeri Totiger11, Justin Taylor, MD12, David T. Teachey, MD13, Markus Müschen, MD-PhD14
AFFILIATIONS
1 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States, Department of Pediatrics, Section of Hematology-Oncology, New Haven, Connecticut, United States
2 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
3 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
4 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
5 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
6 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
7 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
8 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
9 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
10 Division of Pediatric Hematology/Oncology, Cancer and Blood Disease Institute, Los Angeles, California, United States
11 Division of Hematology, Miami, Florida, United States
12 Division of Hematology, Miami, Florida, United States
13 Division of Oncology and Center for Childhood Cancer Research, Philadelphia, Pennsylvania, United States
14 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
ABSTRACT
Background and Significance: B- and T-cell acute lymphoblastic leukemia (ALL) cells express high levels of the transcription factor LEF1 that forms a complex with β-catenin to drive canonical WNT signaling. Despite high LEF1 expression, lymphoid malignancies lack nuclear β-catenin in contrast to solid tumors in which nuclear accumulation of β-catenin is oncogenic. Instead, lymphoid cells critically depend on high-efficiency β-catenin protein degradation (Cosgun et al., Nat Cancer 2026). Previous work identified the recurrent gain-of-function mutation XPO1-E571K, enhancing nuclear export, in lymphoid malignancies. Here we tested the hypothesis that B- and T-ALL cells not only depend on β-catenin protein degradation but also on XPO1-mediated nuclear export. Selinexor, an inhibitor of XPO1, has demonstrated clinical efficacy in hematologic malignancies and may further exploit this vulnerability.
Results: To identify XPO1 cargo proteins, we studied B-ALL cells with SILAC-based mass spectrometry after nuclear and cytoplasmic fractionation in B-ALL cells and treatment with the XPO1 inhibitor leptomycin B. Re-analysis of these data revealed b-catenin as a top-ranked protein with 2.8-fold increase in nuclear to cytoplasmic ratio (P=5E-05) after XPO1 inhibition, exceeding ratios of TP53 and other known XPO1 cargo proteins. Using computational tool LocNES, a previously unrecognized leucine-rich nuclear export signal (NES) within the β-catenin N-terminal region was identified. Reconstitution of β-catenin knockout B-ALL cells with wild-type or NES-mutant β-catenin confirmed the functional significance of the NES. Deletion of this candidate NES within β-catenin resulted in a 2-fold increase in nuclear accumulation compared to the wild-type control. NALM6 cells that were engineered with the XPO1-E571K gain-of-function mutation were significantly more resistant to pharmacological induction of β-catenin accumulation by GSK3B-inhibition. This finding suggests that more efficient nuclear export (XPO1-E571K) of b-catenin can in part compensate for reduced degradation efficiency (GSK3B-inhibition). Interestingly, chemogenomic CRISPR screens of the clinical XPO1 inhibitor selinexor identified GSK3B as a top synthetic lethal gene deletion in NALM6 B-ALL cells. We therefore evaluated selinexor in combination with LY2090314, a GSK3B inhibitor that showed favorable safety and PK/PD profiles in clinical trials. Nuclear β-catenin accumulation was quantified via subcellular fractionation Western blot and immunofluorescence. Combined XPO1 and GSK3B inhibition resulted in synergistic nuclear β-catenin accumulation and exacerbated cell death. Averaging across B- and T-ALL cell lines and PDX models, the highest Zero Interaction Potency (ZIP) synergy scores were 28.4 (B-ALL; n=4) and 26.1 (T-ALL; n=4). Dual XPO1 and GSK3B inhibition was administered to NSG mice bearing high-risk patient-derived xenograft (PDX) in-vivo models (relapsed Ph-like and ETP T-ALL). Combined XPO1 and GSK3B inhibition significantly prolonged survival (vehicle vs combination P=0.004, selinexor vs combination P=0.003, LY2090314 vs combination P=0.018) in relapsed Ph-like B-ALL and ETP T-ALL PDX models.
Conclusions: This study identified β-catenin as a previously unrecognized and functionally significant cargo protein of XPO1 in acute lymphoblastic leukemia. Mutation of a novel b-catenin NES provided structural evidence for XPO1-mediated nuclear export. These findings support a model in which XPO1 functions as a critical safeguard in lymphoid leukemias by exporting toxic b-catenin out of the nucleus for degradation. Here we describe a promising combinatorial strategy for the treatment of high-risk B- and T-ALL with combined inhibition of nuclear export and β-catenin protein degradation to trap toxic β-catenin within the nucleus. This combination produces strikingly synergistic effects with robust β-catenin nuclear accumulation and leukemic cell death in-vitro and in-vivo. Because this vulnerability is shared across the B- and T-lymphocytic lineage rather than confined to a single subtype, the strategy may benefit a broad population of high-risk patients who lack effective targeted therapies. Given selinexor’s FDA-approval for use in multiple myeloma and the clinical trial safety data associated with existing GSK3β inhibitors, this strategy is poised for rapid translation into clinical trials.
DISCLOSURES
Jodi Forward, MD: No relevant conflicts of interest to declare.